SKYEPHARMA PLC
Form 6-K
September 02, 2005

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2005

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
_____

For Immediate Release

DATE OF RELEASE OF INTERIM RESULTS
FOR THE SIX MONTHS ENDING 30 JUNE 2005
UPDATE ON FLUTIFORM NEGOTIATIONS

LONDON, UK, 2 September 2005 - SkyePharma plc (LSE: SKP, NASDAQ: SKYE) will announce its Interi
months ending 30 June 2005 on Wednesday 28 September 2005. These results will be the first presen
Financial Reporting Standards.

SkyePharma announced at the end of April that it had negotiated Heads of Terms with a major glob
company for the US rights to Flutiform . SkyePharma has now discontinued contract negotiations
However, as indicated in July, the April announcement created considerable competitive interest
Flutiform . As a result, SkyePharma remains in active negotiations with several companies, incl
discussions with another major global pharmaceutical company for worldwide rights to Flutiform .

Michael Ashton, SkyePharma's Chief Executive, said: "Flutiform 's prospects continue to impro
its profile will make it superior to competing products in this fast-growing market, already
$5 billion. A number of companies remain actively interested in licensing the product, withi
structures including the retention of co-promotion rights by SkyePharma. Progress towards fil
remains on track and Phase III trials are planned to commence early next year. With estimated pea
well in excess of $1 billion, we remain convinced of our ability to deliver significant value t

For further information please contact:

SkyePharma PLC	**+44 207 491 1777**
Michael Ashton, Chief Executive Officer	
Peter Laing, Director of Corporate Communications	**+44 207 491 5124**
Sandra Haughton, US Investor Relations	**+1 212 753 5780**
Buchanan Communications	**+44 207 466 5000**
Tim Anderson / Mark Court / Rebecca Skye Dietrich	

Notes for editors:
About SkyePharma
SkyePharma develops pharmaceutical products benefiting from world-leading drug delivery techno
easier-to-use and more effective drug formulations. There are now eleven approved and marketed p
SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, sup
solubilisation capabilities. For more information, visit www.skyepharma.com.

About Flutiform
Flutiform is a fixed-dose combination of the inhaled corticosteroid fluticasone with the long-a
bronchodilator formoterol in an HFA-powered metered-dose aerosol inhaler. Flutiform , which is
the treatment of asthma and chronic obstructive pulmonary disease (COPD), has completed Phase II

*Certain statements in this news release are forward-looking statements and are made in reliance o
provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes th
reflected in these forward-looking statements are reasonable, it can give no assurance that these
materialize. Because the expectations are subject to risks and uncertainties, actual results may
from those expressed or implied by the forward-looking statements based upon a number of factors,
in SkyePharma's 20-F and other documents on file with the SEC. Factors that could cause differenc
results and those implied by the forward-looking statements contained in this news release includ
limitation, risks related to the development of new products, risks related to obtaining and main
approval for existing, new or expanded indications of existing and new products, risks related to
ability to manufacture products on a large scale or at all, risks related to SkyePharma's and its
partners' ability to market products on a large scale to maintain or expand market share in the f
customer requirements, competition and technological change, risks related to regulatory complia
product liability claims, risks related to the ownership and use of intellectual property, and r
SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to revise or update an*

statement to reflect events or circumstances after the date of this release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: September 2, 2005